Wei Li-Li, Chen Yong, Yu Qiong-Yang, Wang Yuhui, Liu George
Key Laboratory of Molecular Cardiovascular Science Ministry of Education; Institute of Cardiovascular Sciences, Health Science Center, Peking University, Beijing 100191, China; School of Medicine, Shihezi University, Shihezi City, Xinjiang Uygur Autonomous Region 832000, China.
Department of Neurology, Peking University Third Hospital, Beijing 100191, China.
Brain Res. 2018 Mar 1;1682:61-70. doi: 10.1016/j.brainres.2017.12.039. Epub 2017 Dec 30.
Almost all of the candidate drugs for ischemic stroke failed to be translated from bench to beside. One important reason is that animals used in experimental studies cannot mimic ischemic patients due to lack of comorbidities like hypertension, diabetes and obesity. Therefore, it is better to test candidate drugs not only in normal animals but also in animals with comorbidities. Patchouli alcohol (PA), a natural tricyclic sesquiterpene in the traditional Chinese herb Pogostemonisherba, is well recognized for its anti-inflammation function in various inflammatory diseases. And as inflammation plays a very important role in cerebral ischemia/reperfusion (I/R) injury process and determines the ultimate brain damage, we hypothesized that PA could protect against cerebral I/R injury through its anti-inflammation ability. In this study, the effects of PA on cerebral I/R injury were evaluated in normal mice and obese mice. In normal mice with cerebral I/R injury, PA treatment reduced the infarct volume and neurological deficits in a dose- and time-dependent manner. PA treatment alleviated BBB dysfunction, inhibited mRNA and protein levels of TNF-α and IL-1β and modulated the activation of MAPKs signaling pathways. Moreover, PA also reduced infarct volume, alleviated the BBB dysfunction and inhibited inflammation in ob/ob mice with cerebral I/R injury. In conclusion, we demonstrated for the first time that PA could protect against cerebral I/R injury not only in normal mice but also in obese mice via inhibiting inflammation, suggesting that PA can be a potential drug for clinical treatment of ischemic stroke.
几乎所有用于缺血性中风的候选药物都未能从实验室成功转化到临床应用。一个重要原因是实验研究中使用的动物由于缺乏高血压、糖尿病和肥胖等合并症,无法模拟缺血性中风患者的情况。因此,在正常动物以及患有合并症的动物中测试候选药物会更好。广藿香醇(PA)是传统中药广藿香中的一种天然三环倍半萜,因其在各种炎症性疾病中的抗炎作用而广为人知。由于炎症在脑缺血/再灌注(I/R)损伤过程中起着非常重要的作用,并决定最终的脑损伤程度,我们推测PA可能通过其抗炎能力来保护脑组织免受I/R损伤。在本研究中,我们评估了PA对正常小鼠和肥胖小鼠脑I/R损伤的影响。在患有脑I/R损伤的正常小鼠中,PA治疗以剂量和时间依赖性方式减少了梗死体积并改善了神经功能缺损。PA治疗减轻了血脑屏障功能障碍,抑制了TNF-α和IL-1β的mRNA和蛋白水平,并调节了丝裂原活化蛋白激酶(MAPKs)信号通路的激活。此外,PA还减少了患有脑I/R损伤的ob/ob肥胖小鼠的梗死体积,减轻了血脑屏障功能障碍并抑制了炎症反应。总之,我们首次证明PA不仅可以在正常小鼠中,而且可以在肥胖小鼠中通过抑制炎症来保护脑组织免受I/R损伤,这表明PA可能成为临床治疗缺血性中风的潜在药物。